Now live: Pro — the full 13F research suite for serious investorsSee pricing →
← Tracker

Institutional

Commodore Capital LP

CIK 0001831942
$1.73B
Reported AUM
36
Positions
Q1 2026
Period
2026-05-15
Filed

The Brief · Commodore Capital LP · Q1 2026

AI · grounded in 13F

Commodore Capital LP exited its position in Terns Pharmaceuticals Inc 430, reducing exposure by $59.6M. The fund established new positions in Erasca Inc ERAS and Damora Therapeutics Inc DMRA, adding $51.4M and $50.2M respectively. Other notable activity includes new stakes in Definium Therapeutics Inc DFTX and Eyepoint Inc EYPT, alongside a full exit from Oruka Therapeutics Inc.

Portfolio · Q1 2026

RLAY$169.2MALKS$148.5MELVN$128.4MCOGT$111.2MSYRE$96.5MTYRA$94.8MCLDXNUVLAMLXKYMRANROPHVSOther$552.6MCL

Top holdings

#StockIssuerPriceDay %1Y Gr.5Y Gr.Value% of bookΔ shares (QoQ)Status
1RLAYRELAY THERAPEUTICS INC$19.455.88%461.61%-41.09%$169.2M9.79%HELD
2ALKSALKERMES PLC$50.033.50%88.84%60.39%$148.5M8.59%HELD
3ELVNENLIVEN THERAPEUTICS INC$53.951.85%188.04%181.58%$128.4M7.43%HELD
4COGTCOGENT BIOSCIENCES INC$41.364.52%257.28%391.91%$111.2M6.43%HELD
5SYRESPYRE THERAPEUTICS INC$101.503.71%524.23%-44.00%$96.5M5.58%HELD
6TYRATYRA BIOSCIENCES INC$33.066.27%209.64%43.41%$94.8M5.48%HELD
7CLDXCELLDEX THERAPEUTICS INC NEW$38.492.61%70.78%-28.02%$85.5M4.95%HELD
8NUVLNUVALENT INC0.00%$85.4M4.94%HELD
9AMLXAMYLYX PHARMACEUTICALS INC$20.755.17%151.20%-41.09%$78.5M4.54%HELD
10KYMRKYMERA THERAPEUTICS INC$107.011.67%147.44%71.07%$62.5M3.61%HELD
11ANROALTO NEUROSCIENCE INC$28.637.15%838.69%86.51%$61.2M3.54%HELD
12PHVSPHARVARIS N V$33.883.86%67.35%65.78%$54.2M3.14%HELD
13ERASERASCA INC$18.685.42%1243.88%-21.87%$51.4M2.97%HELD
14DMRADAMORA THERAPEUTICS INC$29.213.11%811.39%-73.74%$50.2M2.91%HELD
15XENEXENON PHARMACEUTICALS INC$64.191.73%106.89%257.51%$48.0M2.78%HELD
16DFTXDEFINIUM THERAPEUTICS INC$44.495.53%414.87%0.24%$37.8M2.19%HELD
17LBRXLB PHARMACEUTICALS INC$40.904.87%142.26%152.32%$37.0M2.14%HELD
18EYPTEYEPOINT INC$12.867.89%22.76%8.96%$36.4M2.11%HELD
19NRIXNURIX THERAPEUTICS INC$23.58-0.08%110.51%-27.80%$35.3M2.04%HELD
20CRVSCORVUS PHARMACEUTICALS INC$13.191.15%221.71%483.63%$33.0M1.91%HELD
21ASMBASSEMBLY BIOSCIENCES INC$26.063.78%36.11%-45.08%$27.8M1.61%HELD
22CATXPERSPECTIVE THERAPEUTICS INC$2.994.18%-22.01%-55.16%$26.4M1.53%HELD
23SLNOSOLENO THERAPEUTICS INC$21.8M1.26%HELD
24OCULOCULAR THERAPEUTIX INC$8.471.32%-29.99%-20.98%$21.8M1.26%HELD
25IPSCCENTURY THERAPEUTICS INC$2.198.42%279.70%-91.85%$19.7M1.14%HELD
26ZURAZURA BIO LTD$5.544.33%272.67%-17.91%$19.3M1.12%HELD
27SABSSAB BIOTHERAPEUTICS INC$3.562.30%59.64%-96.43%$16.9M0.98%HELD
28PALIPALISADE BIO INC$1.960.00%95.05%-99.91%$12.6M0.73%HELD
29KPTIKARYOPHARM THERAPEUTICS INC$7.012.19%74.55%-92.11%$10.9M0.63%HELD
30IKTINHIBIKASE THERAPEUTICS INC$2.283.17%50.00%-83.97%$9.1M0.52%HELD
31ANTXAN2 THERAPEUTICS INC$5.336.18%$8.0M0.46%HELD
32PEPGPEPGEN INC$1.784.09%$7.9M0.46%HELD
33AVTXAVALO THERAPEUTICS INC$19.392.00%$7.2M0.42%HELD
34HLXCHELIX ACQUISITION CORP III$10.510.00%$5.1M0.29%HELD
35LONALEONABIO INC$7.293.55%$4.8M0.28%HELD
36RLMDRELMADA THERAPEUTICS INC$5.354.09%$4.4M0.26%HELD

Source: SEC EDGAR · accession 0001831942-26-000025. 13F discloses long positions only — shorts, foreign equities, and options are excluded.